Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. company information, Employees & Contact Information

Xilio is a Waltham, Massachusetts-based clinical-stage biopharmaceutical company focused on defeating cancer. The company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.

Company Details

Employees
83
Founded
-
Address
828 Winter St, Waltham,massachusetts 02451,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Waltham, Massachusetts
Looking for a particular Xilio Therapeutics, Inc. employee's phone or email?

Xilio Therapeutics, Inc. Questions

News

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - Yahoo Finance

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results Yahoo Finance

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - Sahm

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting Sahm

Xilio Therapeutics CEO René Russo to Present at TD Cowen 45th Annual Health Care Conference - Quiver Quantitative

Xilio Therapeutics CEO René Russo to Present at TD Cowen 45th Annual Health Care Conference Quiver Quantitative

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting - GlobeNewswire

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting GlobeNewswire

Top Xilio Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant